Search
for
Sort by
Research 30 of 1000+
- A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
- Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Title Choice of treatment for severe forms of alopecia areata (case reports)
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase inhibitors in dermatology: a review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Advances in the mechanism and new therapies of alopecia areata
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Under Development JAK Inhibitors for Dermatologic Diseases
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- JAK Inhibitors for Treatment of Alopecia Areata
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review